公开(公告)号：US20120014969A1

公开(公告)日：2012-01-19

申请号：US13181115

申请日：2011-07-12

Applicant: Robert Akita ,  Mark Sliwkowski

Inventor： Robert Akita ,  Mark Sliwkowski

IPC: A61K39/395 ,  C07K16/46 ,  C12N5/16 ,  G01N33/573 ,  A61P25/00 ,  C12N1/21 ,  C12N1/15 ,  C12N5/10 ,  A61P35/00 ,  A61P29/00 ,  C07K16/40 ,  C12N1/19

CPC classification number: C07K16/2863 ,  A61K2039/505 ,  C07K16/32 ,  C07K2317/55 ,  C07K2317/76 ,  G01N33/74 ,  G01N2333/71

Abstract: Antibodies are disclosed which bind to ErbB3 protein and further possess any one or more of the following properties: an ability to reduce heregulin-induced formation of an ErbB2-ErbB3 protein complex in a cell which expresses ErbB2 and ErbB3; the ability to increase the binding affinity of heregulin for ErbB3 protein; and the characteristic of reducing heregulin-induced ErbB2 activation in a cell which expresses ErbB2 and ErbB3.

Abstract translation: 公开了结合ErbB3蛋白并且还具有以下特性中的一种或多种的抗体：在表达ErbB2和ErbB3的细胞中减少asgulin诱导的ErbB2-ErbB3蛋白复合物形成的能力; 增加蛋白对ErbB3蛋白结合亲和力的能力; 以及在表达ErbB2和ErbB3的细胞中减少鸟嘌呤诱导的ErbB2激活的特征。

公开(公告)号：US20110293614A1

公开(公告)日：2011-12-01

申请号：US13130789

申请日：2009-11-24

Applicant: Klaus Elenius ,  Maija Hollmen ,  Mark Sliwkowski

Inventor： Klaus Elenius ,  Maija Hollmen ,  Mark Sliwkowski

IPC: A61K39/395 ,  A61P35/00 ,  G01N33/566 ,  C07K16/40 ,  C12N5/09

CPC classification number: C07K16/40 ,  A61K2039/505 ,  C07K16/32 ,  C07K2317/30 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  G01N33/57492 ,  G01N2333/71

Abstract: Compositions and methods useful for detecting and treating cancers which express the HER4 JM-a isoform are disclosed.

Abstract translation: 公开了用于检测和治疗表达HER4 JM-a同种型的癌症的组合物和方法。

公开(公告)号：US07862817B2

公开(公告)日：2011-01-04

申请号：US11044749

申请日：2005-01-27

Applicant: Camellia W. Adams ,  Leonard G. Presta ,  Mark Sliwkowski

Inventor： Camellia W. Adams ,  Leonard G. Presta ,  Mark Sliwkowski

IPC: A61K39/395 ,  C07K16/28 ,  C12P21/08 ,  C07K14/705

CPC classification number: A61K31/282 ,  A61K31/337 ,  A61K31/525 ,  A61K31/7072 ,  A61K33/24 ,  A61K39/395 ,  A61K45/06 ,  A61K47/6809 ,  A61K2039/505 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/76 ,  Y10S424/80 ,  Y10S424/801 ,  A61K2300/00

Abstract: The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies.

Abstract translation: 本申请描述了人源化抗ErbB2抗体和用抗ErbB2抗体如人源化抗ErbB2抗体治疗癌症的方法。

公开(公告)号：US20100136033A1

公开(公告)日：2010-06-03

申请号：US12609737

申请日：2009-10-30

Applicant: Sharon Erickson ,  Ralph Schwall ,  Mark Sliwkowski ,  Walter Blattler

Inventor： Sharon Erickson ,  Ralph Schwall ,  Mark Sliwkowski ,  Walter Blattler

IPC: A61K39/395 ,  C07K16/00 ,  A61P35/00

CPC classification number: C07K16/3015 ,  A01K67/0271 ,  A01K67/0275 ,  A01K67/0278 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2217/05 ,  A01K2217/052 ,  A01K2227/105 ,  A01K2267/0331 ,  A61K9/0019 ,  A61K39/39558 ,  A61K47/6803 ,  A61K47/6855 ,  A61K47/6871 ,  A61K2039/505 ,  C07K16/2863 ,  C07K16/32 ,  C07K2317/24 ,  C12N15/8509

Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.

Abstract translation: 该应用涉及使用抗ErbB受体抗体 - 美登木素生物碱结合物的治疗方法以及适用于这种方法的制品。 特别地，本发明涉及使用抗ErbB受体抗体 - 美登木素生物碱结合物的ErbB受体指导的癌症治疗。

公开(公告)号：US20100135957A1

公开(公告)日：2010-06-03

申请号：US12639822

申请日：2009-12-16

Applicant: Vincent Danial Fitzpatrick ,  Mark Sliwkowski ,  Richard L. Vandlen

Inventor： Vincent Danial Fitzpatrick ,  Mark Sliwkowski ,  Richard L. Vandlen

IPC: A61K38/20 ,  C07K16/00 ,  C07H21/04 ,  C12N15/63 ,  C12N5/00 ,  C07K16/42 ,  A61K39/395 ,  A61K38/21 ,  A61P35/04 ,  A61P29/00 ,  A61P9/00

CPC classification number: C07K14/71 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/4756 ,  C07K16/32 ,  C07K19/00 ,  Y02A50/466 ,  Y10S435/971

Abstract: Novel chimeric heteromultimer adhesins that bind the ligand of natural heteromultimeric receptors and uses therefor are disclosed. The chimeric molecules of the heteromultimer adhesins comprise an extracellular domain of a heteromultimeric receptor monomer and a multimerization domain for the stable interaction of the chimeric molecules in the adhesin. Specifically disclosed are heteromultimeric adhesins comprising the extracellular domains of ErbB2 and ErbB3 or ErbB2 and ErbB4. The chimeric ErbB heteromultimer adhesins of the present invention are useful as competitive antagonists or agonists of a neuregulin for the treatment of diseases such as various cancers.

Abstract translation: 公开了结合天然异源多聚体受体的配体的新型嵌合杂多聚体粘附素及其用途。 杂多聚体粘附素的嵌合分子包含异源多聚体受体单体的细胞外结构域和用于粘附素中嵌合分子的稳定相互作用的多聚化结构域。 具体公开的是包含ErbB2和ErbB3或ErbB2和ErbB4的细胞外结构域的异源多聚体粘附素。 本发明的嵌合ErbB异源多聚体粘附素可用作神经调节蛋白的竞争性拮抗剂或激动剂用于治疗各种癌症等疾病。

公开(公告)号：US20080226659A1

公开(公告)日：2008-09-18

申请号：US11949351

申请日：2007-12-03

Applicant: Sharon Erickson ,  Ralph Schwall ,  Mark Sliwkowski ,  Walter Blattler

Inventor： Sharon Erickson ,  Ralph Schwall ,  Mark Sliwkowski ,  Walter Blattler

IPC: A61K39/395

CPC classification number: C07K16/3015 ,  A01K67/0271 ,  A01K67/0275 ,  A01K67/0278 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2217/05 ,  A01K2217/052 ,  A01K2227/105 ,  A01K2267/0331 ,  A61K9/0019 ,  A61K39/39558 ,  A61K47/6803 ,  A61K47/6855 ,  A61K47/6871 ,  A61K2039/505 ,  C07K16/2863 ,  C07K16/32 ,  C07K2317/24 ,  C12N15/8509

Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anri-ErbB receptor antibody-maytansinoid conjugates.

Abstract translation: 该应用涉及使用抗ErbB受体抗体 - 美登木素生物碱结合物的治疗方法以及适用于这种方法的制品。 特别地，本发明涉及使用了ErbB受体抗体 - 美登木素生物碱结合物的ErbB受体靶向的癌症疗法。

公开(公告)号：US20080124331A1

公开(公告)日：2008-05-29

申请号：US11733861

申请日：2007-04-11

Applicant: Belinda Cairns ,  Ruihuan Chen ,  Gretchen Frantz ,  Kenneth Hillan ,  Hartmut Koeppen ,  Heidi Phillips ,  Paul Polakis ,  Susan Spencer ,  Victoria Smith ,  P. Williams ,  Thomas Wu ,  Zemin Zhang ,  Mark Sliwkowski

Inventor： Belinda Cairns ,  Ruihuan Chen ,  Gretchen Frantz ,  Kenneth Hillan ,  Hartmut Koeppen ,  Heidi Phillips ,  Paul Polakis ,  Susan Spencer ,  Victoria Smith ,  P. Williams ,  Thomas Wu ,  Zemin Zhang ,  Mark Sliwkowski

IPC: A61K31/70 ,  A61K39/395 ,  A61P43/00 ,  C07H21/04 ,  C07K16/18 ,  C12N5/06 ,  G01N33/574

CPC classification number: G01N33/57484 ,  A61K47/60 ,  A61K47/6803 ,  A61K47/6809 ,  A61K47/6817 ,  A61K47/6839 ,  A61K47/6851 ,  A61K47/6859 ,  A61K51/1006 ,  A61K51/1018 ,  A61K2039/505 ,  C07K16/1072 ,  C07K16/18 ,  C07K16/30 ,  C07K16/303 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77

Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.

公开(公告)号：US20050238640A1

公开(公告)日：2005-10-27

申请号：US11154465

申请日：2005-06-16

Applicant: Mark Sliwkowski

Inventor： Mark Sliwkowski

IPC: A61K47/48 ,  C07K16/32 ,  A61K39/395

CPC classification number: A61K31/282 ,  A61K31/337 ,  A61K31/525 ,  A61K31/7072 ,  A61K33/24 ,  A61K39/395 ,  A61K45/06 ,  A61K47/6809 ,  A61K2039/505 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/76 ,  Y10S424/80 ,  Y10S424/801 ,  A61K2300/00

Abstract: The present application describes methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies, and EGFR-targeted drugs.

Abstract translation: 本申请描述了用抗ErbB2抗体如人源化抗ErbB2抗体和EGFR靶向药物治疗癌症的方法。

公开(公告)号：US07585673B2

公开(公告)日：2009-09-08

申请号：US11173893

申请日：2005-07-01

Applicant: Gabriele Maria Schaefer ,  Mark Sliwkowski

Inventor： Gabriele Maria Schaefer ,  Mark Sliwkowski

IPC: A61K38/18 ,  A61K38/17

CPC classification number: C07K14/71 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/4756 ,  C07K16/32 ,  C07K19/00 ,  Y02A50/466 ,  Y10S435/971

Abstract: A novel member of the heregulin superfamily has been identified which is designated “γ-HRG”. This molecule, secreted by human breast cancer MDA-MB-175 cells, leads to the formation of a constitutive active receptor complex and stimulates the growth of these cells in an autocrine manner. γ-HRG polypeptide and nucleic acid are disclosed, together with various uses therefor (e.g. use of γ-HRG nucleic acid for the recombinant production of γ-HRG). γ-HRG antagonists (e.g. neutralizing antibodies and antisense nucleic acid molecules) as well as uses therefor are also described.

Abstract translation: 已经鉴定了一个被称为“γ-HRG”的蛋白质超家族的新成员。 这种由人乳腺癌MDA-MB-175细胞分泌的分子导致组成型活性受体复合物的形成，并以自分泌的方式刺激这些细胞的生长。 公开了γ-HRG多肽和核酸，以及其各种用途（例如，使用γ-HRG核酸进行γ-HRG的重组生产）。 还描述了γ-HRG拮抗剂（例如中和抗体和反义核酸分子）及其用途。

公开(公告)号：US20070092513A1

公开(公告)日：2007-04-26

申请号：US11581221

申请日：2006-10-13

Applicant: Mary Gerritsen ,  Mark Sliwkowski

Inventor： Mary Gerritsen ,  Mark Sliwkowski

IPC: A61K39/395

CPC classification number: C07K14/82 ,  A61K38/00 ,  C07K14/4756 ,  C07K16/32 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/00 ,  C07K2319/30 ,  G01N33/5061

Abstract: The present invention concerns methods and means for controlling excessive proliferation and/or migration of smooth muscle cells, and in particular for treating stenosis, by using antagonists of a native ErbB4 receptor. The invention further concerns a method for the identification of ErbB4 agonists and antagonists capable of inhibiting or enhancing the proliferation or migration of smooth muscle cells.

Abstract translation: 本发明涉及通过使用天然ErbB4受体的拮抗剂来控制平滑肌细胞的过度增殖和/或迁移，特别是用于治疗狭窄的方法和手段。 本发明还涉及鉴定能够抑制或增强平滑肌细胞增殖或迁移的ErbB4激动剂和拮抗剂的方法。